Has van Anh Ginger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,936 in general payments to van Anh Ginger, MD across 67 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean van Anh Ginger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about van Anh Ginger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

van Anh Ginger, MD

Urology · Seattle, WANPI 1821108309

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,908 of the $2,936 with a category attached, or 65.0%. 24 manufacturers reported payments, led by Medtronic at 46.9% of the total. Reporting peaked in 2024 at $1,749 and has fallen 79.5% since, to $358 in 2025.

$2,936in general payments, 2019–2025

Across 67 payments — averaging $43.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$1K
C. R. Bard, Inc. & Subsidiaries$439
Procept Biorobotics Corporation$173
180 Medical, Inc.$169
Urogen Pharma, Inc.$74
Angiodynamics, Inc.$66
plus $636 from 18 others

What the payments were for

Travel & lodging$1,00334%
Food & beverage$1,90865%
Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	9	$1,378
C. R. Bard, Inc. & Subsidiaries	18	$439
Procept Biorobotics Corporation	3	$173
180 Medical, Inc.	6	$169
Urogen Pharma, Inc.	2	$74
Angiodynamics, Inc.	2	$66
Progenics Pharmaceuticals, Inc.	2	$64
Olympus America Inc.	1	$59
Urovant Sciences Inc	3	$57
Boston Scientific	2	$52
Convatec Inc.	1	$46
Accord Healthcare, Inc.	2	$45
Laborie Medical Technologies Corp.	2	$45
Telix Pharmaceuticals	1	$36
Endo Pharmaceuticals Inc.	2	$35
Valencia Technologies Corporation	1	$34
Immunitybio, Inc.	2	$31
Myriad Genetic Laboratories, Inc.	1	$24
Johnson & Johnson	1	$23
Cook Medical LLC	2	$21
Pfizer	1	$21
Dornier Medtech America, Inc	1	$21
BD	1	$18
Travere Therapeutics, Inc.	1	$4

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INTERSTIM$1,108
AquaBeam Robotic System$113

How this compares

$2,936 in reported general payments places this provider in the 60th percentile of 274 urology providers in Washington.

See all urology providers in Washington →

Medicare billing

Part B allowed, 2024

$190,241

Medicare patients

361

Services billed

6,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	145	$143,261
Oxybutynin Chloride ErOxybutynin Chloride	251	$5,911
Tamsulosin Hcl	249	$5,748
Estradiol	56	$4,470
Finasteride	244	$3,095
Cephalexin	135	$2,402
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	180	$2,205
Trospium Chloride	24	$1,859
Solifenacin Succinate	54	$1,623
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	96	$1,462
Cefdinir	69	$1,330
NitrofurantoinNitrofurantoin Macrocrystal	34	$1,285
Tolterodine Tartrate ErTolterodine Tartrate	18	$1,181
Chlorthalidone	20	$586
Ciprofloxacin Hcl	69	$391

Paid to pharmacies, not to this prescriber.

Other urology in Seattle

James PorterSeattle$471K
Marah HehemannSeattle$213K
Thomas WalshSeattle$186K
Alvaro LucioniSeattle$148K
Una LeeSeattle$116K
George SchadeSeattle$78K
Vi NguyenSeattle$53K
Rogerio HuangSeattle$45K
Cristopher GarlitzSeattle$45K
Sarah PsutkaSeattle$40K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →